JSJeffrey D. Sharon

Jeffrey D. Sharon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey D. Sharon has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Gardi

    Department of Otolaryngology‐Head and Neck Surgery University of California, San Francisco San Francisco California USA

    6 shared publications
  • Kristen K. Steenerson

    Department of Otolaryngology – Head and Neck Surgery Stanford University School of Medicine Palo Alto California USA

    5 shared publications
  • Eric K. Kim

    Department of Otolaryngology–Head and Neck Surgery University of California San Francisco San Francisco California USA

    4 shared publications
  • Maxwell Hum

    Department of Otolaryngology‐Head and Neck Surgery University of California, San Francisco San Francisco California USA

    4 shared publications
  • Roseanne Krauter

    Department of Otolaryngology‐Head and Neck Surgery University of California, San Francisco San Francisco California USA

    4 shared publications
  • Brian Nussenbaum

    Department of Otolaryngology, Washington University, St. Louis, Missouri, United States

    3 shared publications

Latest Publications

  • Video Report of a Drop Attack in Meniére Disease

    by Ana M. Sola, Jeffrey D. Sharon, Nicole T. Jiam

    Was not provided for this article.

  • Visual Motion Sensitivity in Vestibular Migraine

    by Alexandra T. Bourdillon, Jason W. Allen, Jeremy L. Smith, Vishwadeep Ahluwalia, Russell K. Gore, Jeffrey D. Sharon

    Objective: To quantitatively assess visual motion sensitivity in vestibular migraine (VM). Study design: Cohort study. Setting: Single institution. Patients: Prospective cohort of individuals with VM and healthy controls. Interventions: Subjects rated visually induced symptoms while watching 20 videos with varying degrees of optical flow. After each video, participants rated the intensity of their predominant symptom (headache, dizziness, nausea, or fogginess) on a 5-point Likert scale. Main outcome measures: The primary outcome was a composite symptom score (sum of ratings), which was compared with other patient-reported outcome measures, including (1) Dizziness Handicap Inventory, (2) VM-Patient Assessment Tool and Handicap Inventory, and (3) Visual Vertigo Analog Scale, among other headache, cognitive, and psychometric questionnaires. Results: The study enrolled 17 participants with VM and 19 healthy controls. The rate of visual motion sensitivity (any symptom) was significantly higher in the VM arm [71.9% vs. 13.7% in controls, X 2 (4, 705)=245.6, P U =304.0, P P P P =0.01, although not significant after Bonferroni correction). Conclusions: Visual motion sensitivity is more frequent in those with VM than in healthy controls, and symptom scores correlated with other established patient-reported outcome measures, especially the Visual Vertigo Analog Scale. Visual motion sensitivity is a distinct and measurable feature of VM and can inform disease severity and treatment response.

  • A Pilot Study of Virtual Reality‐Vestibular Physical Therapy for Refractory Dizziness

    by Alexandra T. Bourdillon, Evan J. Patel, Ricky Chae, Eliot J. Gann, Alexander Dien, Jeffrey D. Sharon

    Objective: To assess the tolerability and efficacy of Virtual Reality‐Vestibular Physical Therapy (VR‐VPT) in individuals with refractory symptoms after conventional vestibular rehabilitation. Study Design: Prospective cohort study. Setting: Single institution tertiary care practice. Methods: Participants were offered VR‐VPT if they (1) still had symptoms after conventional vestibular physical therapy or (2) were considered to have a specific problem suited to VR‐VPT. Treatment consisted of approximately 8 45‐minute sessions, each directed by a physical therapist. Differences in baseline and posttreatment surveys, provider‐based assessments, and presession and postsession Simulator Sickness Questionnaire (SSQ) scores were analyzed. Results: Among our cohort of 18 participants, there were 10 individuals with vestibular loss (VL), 6 with vestibular migraine (VM), and 4 with Persistent Postural‐Perceptual Dizziness (PPPD), with some participants having more than 1 diagnosis. Significant improvements were seen posttreatment in the Dizziness Handicap Inventory (n = 15, mean difference: −11.7, 95% CI: [−18.2, −5.2], P = .002) and the Functional Gait Assessment (n = 17, mean difference: 2.3, 95% CI: [0.8, 3.8], P = .005). Video head impulse testing and dynamic visual acuity improved in a subset of VL participants who underwent both baseline and posttreatment testing. VR‐VPT sessions did not significantly provoke symptoms captured in SSQ responses, such as nausea (average difference: 0.32 ± 0.68) or general discomfort (average difference: 0.14 ± 0.68). Conclusion: This pilot study suggests that VR‐VPT can be tolerated and may benefit many patients with refractory symptoms, with additional benefits in vestibular function observed in individuals with vestibular loss.

  • Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience

    by Luana G Sousa, James Edward Bates, Payal Anand, Jimmy J Caudell, A Dimitrios Colevas, Christina L Runge, Jeffrey D Sharon, Musaddiq Awan, Beth M Beadle, Jennifer H Choe, et al.

    Background: Cisplatin remains the cornerstone radiosensitizer for definitive and adjuvant chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. However, despite decades of clinical use, many practical aspects of cisplatin administration remain unstandardized in clinical practice and trials. Methods: Drawing on the collective experience of the NRG Oncology Head and Neck Working Group, this consensus article provides practical guidance on the administration of cisplatin during radiation therapy. We review and propose recommendations regarding the timing of chemotherapy and radiation initiation, premedication and hydration regimens by dose, monitoring and grading of cisplatin-induced ototoxicity, and management strategies during cisplatin shortages. Our guidance is informed by clinical trial protocols, retrospective and prospective data, and multidisciplinary expert consensus. We emphasize the importance of protocol flexibility to support equitable trial accrual, minimize treatment delays, and improve patient-centered outcomes. Conclusions: This article offers a unified framework to optimize the use of cisplatin in chemoradiation protocols, improve adherence, reduce toxicity, and preserve oncologic efficacy. Our recommendations are particularly timely in the context of evolving clinical practices and recent cisplatin shortages. Insights from the NRG Oncology collaborative group aim to inform future trial designs and clinical practice guidelines, ensuring consistent and equitable care for patients with head and neck cancer.


  • Calcitonin gene‐related peptide in the audiovestibular system

    by Evan J. Patel, Jeffrey D. Sharon, Morris Levin, Anne E. Luebke

    Objective: This study aimed to summarize and analyze the current literature related to calcitonin gene‐related peptide (CGRP), the vestibular system, and vestibular migraine. Background: CGRP is a neuropeptide that has been implicated in the pathophysiology of migraine. Vestibular migraine (VM) is a subtype of migraine that causes recurring episodes of vestibular symptoms like vertigo and is often associated with migrainous symptoms. Although the pathophysiology of VM is not completely understood, CGRP expression in the central and peripheral vestibular systems has suggested that it may also play a role in this closely related disease. Methods: We performed a synthesis of current literature regarding the neuroanatomy of CGRP and the vestibular system and how CGRP stimulation and blockade affect vestibular function. Data was included from human and animal experiments indexed on PubMed. Results: CGRP expression in rodents was found in the vestibular cerebellum, vestibular nuclei, and in lateral olivocochlear efferent neurons. αCGRP‐null (−/−) mice have a decreased gain of the vestibular‐ocular reflex as well as impaired balance testing. CGRP infusion in rodents causes phonophobia, motion sickness, and imbalance. In vasodilator‐induced migraine models, CGRP expression was increased in central vestibular structures, with associated vestibular dysfunction and motion sensitivity. In humans, monoclonal antibodies targeting the CGRP pathway can reduce dizziness from vestibular migraine. Conclusion: CGRP is expressed in the central and peripheral audiovestibular system and is implicated in the pathophysiology of VM. Preliminary results have shown promise for the treatment of VM with CGRP‐targeted therapies although more high‐level placebo‐controlled data is needed especially for orally administered gepants. Further study is required to better understand how CGRP influences vestibular function and its role in vestibular migraine.


  • Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM‐PATHI) : A narrative review

    by Alireza Sharifi, Ali Kouhi, Kristen K. Steenerson, Jeffrey D. Sharon

    Background: Vestibular migraine (VM) has a wide range of clinical presentations that can have a significant negative impact on quality of life. Currently, there is no objective test available to confirm the diagnosis or measure the severity of VM. The only available tools for assessing disease severity are patient‐reported outcome measures (PROMs), such as the Dizziness Handicap Inventory (DHI). Objective: This manuscript aims to summarize the current knowledge about a newly developed PROM called the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM‐PATHI). Methods: A comprehensive search was conducted across the Web of Science, Scopus, PubMed, and Google Scholar databases up to February 2024, using the keywords “Vestibular migraine,” “VM‐PATHI,” and “Patient‐Reported Outcome Measure.” Only studies involving human participants were included, and no additional restrictions were applied. The reference lists of included studies were also reviewed to identify other eligible studies. The main outcome of interest was the evaluation of VM‐PATHI in patients with VM. Results: The VM‐PATHI is a 25‐item questionnaire divided into six sections: headache equivalents, motion sensitivity, anxiety, cognition, disequilibrium/central audiovestibular disturbance, and emotion/sense of being overwhelmed. This tool has demonstrated good face and content validity, discriminant validity, responsiveness, test–retest reliability, and internal reliability (Cronbach's α : 0.92). Patients with VM are likely to show clinical improvement in symptoms if their VM‐PATHI scores decrease by ≥6 points. Additionally, VM‐PATHI has shown a good correlation with clinical improvement across various treatment modalities. Conclusion: The VM‐PATHI may provide advantages over other PROMs by measuring a wider spectrum of disease‐specific effects of VM. Scores are correlated with the DHI, dizzy days per month, and other quality of life metrics.


  • Open Access

    Rare case of cochlear implant damaged by nearby use of monopolar electrosurgery

    by Evan J. Patel, Colleen Polite, Jeffrey D. Sharon


  • A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study

    by Jeffrey D. Sharon, Roseanne Krauter, Ricky Chae, Adam Gardi, Maxwell Hum, Isabel Allen, Morris Levin

    Objective: To study if galcanezumab is effective for vestibular migraine (VM). Background: There are currently no placebo‐controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene–related peptide–targeted monoclonal antibody for VM. Methods: This was a single site, prospective, double‐blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18–75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM‐PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre‐filled syringe, 240 mg the first month, and 120 mg for the second and third months. Results: Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM‐PATHI score was reduced 5.1 points (95% confidence interval [CI] −13.0 to 2.7) for placebo ( N = 21), and 14.8 points (95% CI −23.0 to −6.5) for galcanezumab ( N = 17), a difference of −9.6 (95% CI −20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI −15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI −31.9 to −12.1), a difference of −13.7 (95% CI −20.4 to −8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of −5.7 days (95% CI −10.7 to −0.7, p = 0.026). No serious adverse events were observed. Conclusions: In this pilot study, galcanezumab was effective in treating VM.


  • A Month of Vestibular Migraine: Symptom Characterization Using Ecological Momentary Assessment

    by Jasmeet Saroya, Max Humwell, Adam Gardi, Ricky Chae, Daniel Wong, Isabel Allen, Jeffrey D. Sharon

    Objective(s): This study investigated the frequency and intensity of vestibular migraine (VM) symptoms using Ecological Momentary Assessment (EMA). This approach was intended to provide insights into the day‐to‐day experiences of individuals with VM, contributing to a more comprehensive understanding of this condition.Methods: Participants reported symptoms to an automated text system, rating their dizziness over the prior 24 h as none, mild, moderate, or severe. Definitive Dizzy Days (DDDs) were defined as days with moderate or severe dizziness. A student's independent group t‐test was used to compare the number of DDDs between VM and probable VM subjects.Results: Sixty‐six subjects were included, with an average of 29 days of pre‐intervention data (SD = 1.4). The average number of days with no dizziness was 3.5 (SD = 6.5), mild dizziness was 9.1 (SD = 6.7), moderate dizziness was 11 (SD = 6.1), and severe dizziness was 5.4 (SD = 6.3). Out of the 66 patients, 52 were classified as VM and 14 as pVM. The average number of DDDs was not significantly different between VM (17.0, SD = 8.3) and pVM (15.3, SD = 10.0) patients, with a two‐tailed p‐value of 0.44.Conclusion: With EMA, we found that the average subject with VM had some degree of dizziness almost every day, and more than 15 DDDs per month.Level of Evidence: III Laryngoscope, 2024


  • Does Catastrophizing Predict Response to Treatment in Patients With Vestibular Disorders? A Prospective Cohort Study

    by Danielle M. Gillard, Maxwell Hum, Adam Gardi, Linda Centore, Jeffrey D. Sharon

    Objective: Determine levels of catastrophizing in patients with vestibular disorders and prospectively evaluate their relationship with patient-reported outcome measures. Study Design: Prospective cohort study. Setting: Tertiary care neurotology vestibular disorders clinic. Patients: Adult patients with various vestibular disorders. Interventions: Patients were given the Dizziness Handicap Inventory (DHI) and the Dizziness Catastrophizing Scale (DCS) at a baseline visit and follow-up visit after treatment. Main outcome measures: Correlation studies were used to determine the relationships between DHI and DCS. Multivariable linear regression was performed to determine the relationship between DCS and DHI change with treatment, accounting for demographic variables. Results: Forty-six subjects completed both the DHI and the DCS before and after treatment. Patients with higher baseline DCS scores had higher baseline DHI scores (p < 0.001). There was a significant improvement in both DHI score (p < 0.001) and DCS (p < 0.001) at follow-up. Patients who had reduction in DCS scores during were more likely to show reduction in DHI scores (p < 0.001). A subset of patients had a mindfulness-based stress reduction program included in their treatment. These patients had a greater reduction in both DCS and DHI scores at follow-up compared with those who received other treatments. Conclusions: Catastrophizing is associated with higher pretreatment DHI scores and worse treatment outcomes. Addressing dizziness catastrophizing may help improve vestibular outcomes.